...
首页> 外文期刊>Brain research >Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer’s disease patients: A CSF and FDG PET study
【24h】

Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer’s disease patients: A CSF and FDG PET study

机译:脑代谢CSF Tau蛋白在阿尔茨海默病患者的大群体中的代谢相关性:CSF和FDG宠物研究

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Aims Physiopathological mechanisms of Alzheimer’s disease (AD) are still matter of debate. Especially the role of amyloid β and tau pathology in the development of the disease are still matter of debate. Changes in tau and amyloid β peptide concentration in cerebrospinal fluid (CSF) and hypometabolic patterns at fluorine-18 fluorodeoxyglucose ( 18 F-FDG) PET scanning are considered as biomarkers of AD. The present study was aimed to evaluate the relationships between the concentrations of CSF total Tau (t-Tau), phosphorilated Tau (p-Tau) and Aβ 1–42 amyloid peptide with 18 F-FDG brain distribution in a group of patients with AD. Materials and methods We examined 131 newly diagnosed AD patients according to the NINCDS-ADRDA criteria and 20 healthy controls. The mean (±SD) age of the patients was 70 (±7)?years; 57 were male and 74 were female. All patients and controls underwent a complete clinical investigation, including medical history, neurological examination, mini-mental state examination (MMSE), a complete blood screening (including routine exams, thyroid hormones and a complete neuropsychological evaluation). Structural MRI was performed not earlier than 1 month before the 18 F-FDG PET/CT. The following patients were excluded: those with isolated deficits and/or unmodified MMSE (=25/30) on revisit (period of follow-up: 6, 12 and 18?months); patients who had had a clinically manifest acute stroke in the last 6?months with a Hachinsky score greater than 4; and patients with radiological evidence of subcortical lesions. All AD patients were taken off cholinesterase inhibitor treatment throughout the study. We performed lumbar puncture and CSF sampling for diagnostic purposes 2?weeks (±2?days) before the PET/CT scan. The relationship between brain F-FDG uptake and CSF biomarkers was analysed using statistical parametric mapping (SPM8; Wellcome Department of Cognitive Neurology, London, UK) implemented in Matlab R2012b using the MMSE score, sex and age, and other CSF biomarkers as covariates. Results t-Tau, p-Tau and Aβ(1–42) in CSF resulted 774?±?345?pg/ml, 98?±?64?pg/ml and 348.8?±?111?pg/ml respectively. SPM analysis showed a significant negative correlation between CSF t-Tau and 18 F FDG uptake in right temporal, parietal and frontal lobe (Brodmann areas, BA, 20, 40 and 8; P fdr and few corr? Conclusions t-Tau deposition in brain is related to temporal, parietal and frontal hypometabolism in AD.
机译:摘要Alzheimer疾病(广告)的旨在对辩论的重要机制。特别是淀粉样蛋白β和TAU病理在疾病发展中的作用仍然是辩论的重要性。脑脊液(CSF)中Tau和淀粉样蛋白β肽浓度的变化和氟-18氟脱氧葡萄糖(18 f-FDG)PET扫描的低抑郁型图案被认为是AD的生物标志物。目前的研究旨在评估CSF总Tau(T-Tau),磷酸化Tau(P-Tau)和Aβ1-42淀粉样蛋白肽之间的关系,其中AD的一组患者中的18例F-FDG脑分布。根据Nincds-Adrda标准和20个健康对照,我们检查了131名新诊断的AD患者。患者的平均值(±SD)年龄为70(±7)?岁; 57是男性,74是女性。所有患者和对照都经历了完整的临床调查,包括病史,神经检查,迷你精神状态检查(MMSE),完整的血液筛查(包括常规检查,甲状腺激素和完全神经心理学评估)。结构MRI在18 F-FDG PET / CT之前未早于1个月进行。不包括以下患者:具有孤立的赤字和/或未修改的MMSE(= 25/30)的那些,Revisit(随访时间:6,12和18个月);在过去的6个月中患有临床表现急性卒中的患者,HOCHINSKY得分大于4;和患者具有皮质病变的放射性证据。所有AD患者均在整个研究中脱掉胆碱酯酶抑制剂治疗。我们在PET / CT扫描之前进行了诊断目的进行腰椎穿刺和CSF采样2?周(±2±2天)。使用MATLAB R2012B在Matlab R2012B在Matlab R2012B中实施的统计参数测绘(SPM8; CSF的CSF的CSF生物标志物之间的关系使用MASE评分,性别和年龄以及其他CSF生物标志物作为协变量,分析了统计参数映射(SPM8;康吉,英国)的关系。结果T-Tau,P-Tau和Aβ(1-42)在CSF中产生774°α≤345?PG / mL,98→±64〜±64.α,分别为348.8? SPM分析显示CSF T-TAU和18 F FDG摄取之间的显着的负相关性,右侧颞叶(Brodmann地区,BA,20,40和8; P FDR和很少腐蚀?结论T-Tau沉积在大脑中与广告中的颞率,俯仰和额度高乳腺醇相关有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号